Clinical Trials Browser

Phase 1/2 × Non-Muscle Invasive Bladder Neoplasms × 1 year × Clear all

Non-Muscle Invasive Bladder Neoplasms

NCT07445308 2026-03-03

The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NMIBC, and to Determine the RP2D of SPGL008 Alone or in Combination With BCG.To Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG.

Phase 1/2 Not yet recruiting

120 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06637423 2026-02-19

TroFuse-027

Phase 1/2 Recruiting

32 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT04752722 2026-01-26

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Phase 1/2 Recruiting

350 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT05544552 2026-01-12

SURF301

Phase 1/2 Active not recruiting

310 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis, Urologic Neoplasms

NCT02138734 2025-10-16

A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

Phase 1/2 Recruiting

596 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms

NCT06704191 2025-09-22

In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial

Phase 1/2 Recruiting

40 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT07064863 2025-07-17

BCG-TIME

Phase 1/2 Not yet recruiting

31 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Neoplasms

NCT04179162 2025-06-13

Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment

Phase 1/2 Active not recruiting

54 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06800963 2025-05-16

ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG

Phase 1/2 Not yet recruiting

40 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

Clinical Trials

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NMIBC, and to Determine the RP2D of SPGL008 Alone or in Combination With BCG.To Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG.

TroFuse-027

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

SURF301

A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial

BCG-TIME

Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment

ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG